These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 20082451

  • 1. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators.
    Cancer; 2010 Mar 01; 116(5):1272-80. PubMed ID: 20082451
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
    Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin RA.
    Oncology; 2010 Mar 01; 78(5-6):340-7. PubMed ID: 20733337
    [Abstract] [Full Text] [Related]

  • 3. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S.
    Jpn J Clin Oncol; 2007 Oct 01; 37(10):755-62. PubMed ID: 17951335
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R.
    Clin Cancer Res; 2006 Dec 15; 12(24):7271-8. PubMed ID: 17189398
    [Abstract] [Full Text] [Related]

  • 5. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
    Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.
    J Clin Oncol; 2006 Jun 01; 24(16):2505-12. PubMed ID: 16636341
    [Abstract] [Full Text] [Related]

  • 6. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H.
    BJU Int; 2011 Dec 01; 108(11):1813-9. PubMed ID: 21481133
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib for metastatic renal cancer: the Princess Margaret experience.
    Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ.
    Am J Clin Oncol; 2008 Apr 01; 31(2):182-7. PubMed ID: 18391604
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS, Manchen B.
    Clin J Oncol Nurs; 2007 Oct 01; 11(5):649-56. PubMed ID: 17962173
    [Abstract] [Full Text] [Related]

  • 9. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E.
    Oncology; 2007 Oct 01; 73(3-4):204-9. PubMed ID: 18418013
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Oct 01; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.
    J Clin Oncol; 2009 Jul 10; 27(20):3312-8. PubMed ID: 19451442
    [Abstract] [Full Text] [Related]

  • 12. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
    Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B.
    Ann Oncol; 2011 Aug 10; 22(8):1812-23. PubMed ID: 21324953
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
    Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP.
    J Clin Oncol; 2009 Sep 20; 27(27):4462-8. PubMed ID: 19652060
    [Abstract] [Full Text] [Related]

  • 15. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.
    J Clin Oncol; 2009 Sep 10; 27(26):4274-80. PubMed ID: 19652055
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib in renal cell carcinoma.
    Arranz JÁ, Climent MÁ, González-Larriba JL, León L, Maroto JP.
    Crit Rev Oncol Hematol; 2011 Nov 10; 80(2):314-22. PubMed ID: 21419641
    [Abstract] [Full Text] [Related]

  • 17. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
    Ueda T, Imamura Y, Komaru A, Fukasawa S, Sazuka T, Suyama T, Naya Y, Nihei N, Ichikawa T, Maruoka M.
    Int J Urol; 2010 Sep 10; 17(9):811-5. PubMed ID: 20649824
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
    Amato R, Zhai J, Willis J, Saxena S, DeFoe M.
    Clin Genitourin Cancer; 2012 Sep 10; 10(3):153-8. PubMed ID: 22551785
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK.
    Jpn J Clin Oncol; 2010 Aug 10; 40(8):768-73. PubMed ID: 20494947
    [Abstract] [Full Text] [Related]

  • 20. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
    Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L, Gianni L.
    Anticancer Drugs; 2009 Aug 10; 20(7):616-24. PubMed ID: 19739318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.